Financhill
Back

Xeris Biopharma Holdings 10K Form

Buy
88

XERS
Xeris Biopharma Holdings

Last Price:
3.34
Seasonality Move:
0.46%

7 Day Trial

ALL ACCESS PASS

$ 7

Receive XERS News And Ratings

See the #1 stock for the next 7 days that we like better than XERS

XERS Financial Statistics

Sales & Book Value

Annual Sales: $163.91M
Cash Flow: $-10.75M
Price / Cash Flow: 0
Annual Sales: $-0.13
Price / Book: 0

Profitability

EPS (TTM): -0.42000
Net Income (TTM): $-59.56M
Gross Margin: $135.27M
Return on Equity: 0%
Return on Assets: -18.08%

Xeris Biopharma Holdings Earnings Forecast

Key Xeris Biopharma Holdings Financial Ratios

  • The Gross Profit Margin over the past 8 years for XERS is 82.52%.
  • The Selling, General & Administrative Expenses for XERS have been equal to 89.13% of Gross Profit Margin.
  • The Research & Development expenses have been 13.63% of Revenue.
  • The Interest Expense is -42.74% of Operating Income.
  • The Net Earning history of XERS is -37.98% of Total Revenues.
  • Per Share Earnings over the last 8 years have been positive in 6 years.

Xeris Biopharma Holdings Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: XERS
CUSIP: 98422L
Website: xerispharma.com

Debt

Debt-to-Equity Ratio: -11.95
Current Ratio: 2.26
Quick Ratio: 1.59

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

XERS Technical Analysis vs Fundamental Analysis

Buy
88
Xeris Biopharma Holdings (XERS) is a Buy

Is Xeris Biopharma Holdings a Buy or a Sell?